Biomarkers.

Background: With the increase in life expectancy and the rising prevalence of Alzheimer's Disease (AD), the integration of biomarkers for early diagnosis is crucial. The Mayo Preclinical Alzheimer's Cognitive Composite (Mayo-PACC), encompassing the Rey-Auditory Verbal Learning Test (RAVLT), Trail Making Test - B (TMT B), and semantic fluency, is designed to detect cognitive changes in preclinical AD. This study investigates gender-based differences in the predictive efficacy of Mayo-PACC for AD biomarkers following the ATN (Amyloid, Tau, Neurodegeneration) criteria.